ProNGF is a potential diagnostic biomarker for thyroid cancer

Sam Faulkner; Severine Roselli; Yohann Demont; Jay Pundavela; Genevieve Choquet; Philippe Leissner; Christopher Oldmeadow; John Attia; Marjorie M. Walker; Hubert Hondermarck

doi:10.18632/oncotarget.8652

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

ProNGF is a potential diagnostic biomarker for thyroid cancer

Sam Faulkner _, Severine Roselli, Yohann Demont, Jay Pundavela, Genevieve Choquet, Philippe Leissner, Christopher Oldmeadow, John Attia, Marjorie M. Walker and Hubert Hondermarck

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2016; 7:28488-28497. https://doi.org/10.18632/oncotarget.8652

Metrics: PDF 1995 views | HTML 2452 views | ?

Abstract

Sam Faulkner1,2,*, Severine Roselli1,2,*, Yohann Demont3,7, Jay Pundavela1,2, Genevieve Choquet4, Philippe Leissner4, Christopher Oldmeadow5, John Attia2,6, Marjorie M. Walker2,6, Hubert Hondermarck1,2

1School of Biomedical Sciences & Pharmacy, Faculty of Health and Medicine, University of Newcastle, Callaghan NSW 2308, Australia

2Hunter Medical Research Institute, University of Newcastle, New Lambton NSW 2305, Australia

3Inserm U908, Growth Factor Signaling and Functional Proteomics of Breast Cancer, University of Lille, 59655 Villeneuve d’Ascq, France

4Medical Diagnostic Discovery Department, bioMérieux, 69280 Marcy l’Etoile, France

5School of Mathematical and Physical Sciences, Faculty of Science and Information Technology, University of Newcastle, Callaghan NSW 2308, Australia

6School of Public Health & Medicine, Faculty of Health and Medicine, University of Newcastle, Callaghan NSW 2308, Australia

7Present address: INSERM U1138 team 11, Centre de Recherche des Cordeliers, 75006 Paris, France

*These authors have contributed equally to this work

Correspondence to:

Hubert Hondermarck, email: [email protected]

Keywords: growth factors, proNGF, thyroid cancer, diagnostic biomarker

Received: January 11, 2016 Accepted: March 28, 2016 Published: April 08, 2016

ABSTRACT

The precursor for nerve growth factor (proNGF) is expressed in some cancers but its clinicopathological significance is unclear. The present study aimed to define the clinicopathological significance of proNGF in thyroid cancer. ProNGF expression was analysed by immunohistochemistry in two cohorts of cancer versus benign tumors (adenoma) and normal thyroid tissues. In the first cohort (40 thyroid cancers, 40 thyroid adenomas and 80 normal thyroid tissues), proNGF was found overexpressed in cancers compared to adenomas and normal samples (p<0.0001). The area under the receiver-operating characteristic (ROC) curve was 0.84 (95% CI 0.75-0.93, p<0.0001) for cancers versus adenomas, and 0.99 (95% CI 0.98-1.00, p<0.0001) for cancers versus normal tissues. ProNGF overexpression was confirmed in a second cohort (127 cancers of various histological types and 55 normal thyroid tissues) and using a different antibody (p<0.0001). ProNGF staining intensity was highest in papillary carcinomas compared to other histological types (p<0.0001) and there was no significant association with age, gender, tumor size, stage and lymph node status. In conclusion, proNGF is increased in thyroid cancer and should be considered as a new potential diagnostic biomarker.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 8652

Publication Alerts

Research Papers:

ProNGF is a potential diagnostic biomarker for thyroid cancer

Abstract